HC Wainwright Has Lowered Expectations for Alumis (NASDAQ:ALMS) Stock Price

Alumis (NASDAQ:ALMS - Get Free Report) had its price objective lowered by stock analysts at HC Wainwright from $15.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 227.10% from the stock's previous close. HC Wainwright also issued estimates for Alumis' Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

A number of other research firms have also commented on ALMS. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $25.86.

Alumis Price Performance

ALMS traded down $0.03 during trading on Tuesday, hitting $4.28. 181,460 shares of the company traded hands, compared to its average volume of 317,293. The stock's fifty day moving average is $5.50 and its 200 day moving average is $7.66. Alumis has a one year low of $3.18 and a one year high of $13.53.

Insider Activity

In other Alumis news, CEO Martin Babler purchased 15,650 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was acquired at an average price of $6.44 per share, for a total transaction of $100,786.00. Following the purchase, the chief executive officer now owns 106,454 shares of the company's stock, valued at approximately $685,563.76. This represents a 17.23 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Colowick acquired 16,104 shares of the stock in a transaction dated Tuesday, April 1st. The stock was acquired at an average price of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the transaction, the director now directly owns 16,104 shares of the company's stock, valued at approximately $112,244.88. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in shares of Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after buying an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Alumis in the 4th quarter valued at $79,000. Rhumbline Advisers lifted its stake in Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after purchasing an additional 2,949 shares in the last quarter. Marshall Wace LLP purchased a new stake in Alumis in the 4th quarter worth $108,000. Finally, XTX Topco Ltd bought a new position in shares of Alumis during the 4th quarter valued at about $129,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.